Dual-Targeting Nanoplatform Integrating Metabolic Glycan Labeling and Bioorthogonal Chemistry for Precise Delivery of Oxaliplatin to PSMA-Positive Prostate Cancer
ACS Macro Letters · 2026
DOI: 10.1021/acsmacrolett.6c00402 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Macro Letters, 2026. Verfasst von Guoliang Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Henan University, Kaifeng475000, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Oxaliplatin, Glutamate Carboxypeptidase II, Antigens, Surface. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key R&D and Promotion Special Project in Henan Province, First Affiliated Hospital, Henan University.
Abstract (Originalsprache)
Platinum-based chemotherapy drugs are widely used in the treatment of various cancers due to their broad antitumor spectrum, but their clinical application is severely limited by significant systemic toxicity resulting from nonspecific cytotoxicity. Prostate-specific membrane antigen (PSMA), which is highly overexpressed in most prostate cancer (PCa) cells, presents a promising target for tumor-selective drug delivery. In this study, we designed and synthesized a novel dual-targeting nanoplatform that combines metabolic glycan labeling and bioorthogonal chemistry for the precise delivery of oxaliplatin (OXP) to PSMA-positive prostate cancer cells. The nanoplatform (DDM-NPs) is functionalized with DUPA, a high-affinity PSMA ligand, and encapsulates Ac4ManNAz for metabolic cell surface engineering. Subsequently, a bioorthogonal reaction between the azido-labeled cells and the bicyclo[6.1.0]non-4-yne (BCN)-conjugated prodrug (BCN-OXP) enhanced cellular uptake and cytotoxicity in PSMA-high-expressed cell lines (22Rv1) compared to PSMA-low-expressed cells (PC-3) in vitro and in vivo. Our work establishes a promising strategy to enhance the therapeutic index of platinum drugs through active targeting and bioorthogonal reactions, offering a potential avenue for more effective and safer prostate cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Henan University, Kaifeng475000, China.
- College of Synthetic Biology and Pharmaceutical Engineering, Henan University, Kaifeng475000, China.
- School of Pharmacy, Henan University, Kaifeng475000, China.
- Peking University First Hospital , Beijing, 100034, China.
ORCID-Profile: Jing Ma, Jiajia Wang
Förderung
- National Natural Science Foundation of China
- Key R&D and Promotion Special Project in Henan Province
- First Affiliated Hospital, Henan University
- Joint Construction Project of Henan Medical Science and Technology Project
Zitieren
APA
Xu, G., Chang, R., Huang, S., Ding, H., Zhang, W., Chu, S., Gao, F., Zhao, S., Wang, L., Zhou, L., Ma, J., & Wang, J. (2026). Dual-Targeting Nanoplatform Integrating Metabolic Glycan Labeling and Bioorthogonal Chemistry for Precise Delivery of Oxaliplatin to PSMA-Positive Prostate Cancer. ACS Macro Letters. https://doi.org/10.1021/acsmacrolett.6c00402
Vancouver
Xu G, Chang R, Huang S, Ding H, Zhang W, Chu S, et al. Dual-Targeting Nanoplatform Integrating Metabolic Glycan Labeling and Bioorthogonal Chemistry for Precise Delivery of Oxaliplatin to PSMA-Positive Prostate Cancer. ACS Macro Letters. 2026. doi:10.1021/acsmacrolett.6c00402
BibTeX
@article{Xu2026,
author = {Xu, Guoliang and Chang, Renhao and Huang, Song and Ding, Huijiao and Zhang, Wei and Chu, Songshen and Gao, Feiyang and Zhao, Shankai and Wang, Lianqu and Zhou, Liqun and Ma, Jing and Wang, Jiajia},
title = {Dual-Targeting Nanoplatform Integrating Metabolic Glycan Labeling and Bioorthogonal Chemistry for Precise Delivery of Oxaliplatin to PSMA-Positive Prostate Cancer},
journal = {ACS Macro Letters},
year = {2026},
doi = {10.1021/acsmacrolett.6c00402}
}
EUVIMED